Loading...
European immuno-oncology profiling platform2025-05-16T15:29:11+01:00

IMMUcan, an integrated European immuno-oncology profiling platform

Immune checkpoint inhibitors have shown promising results in some cancer types, but biomarkers to select patients that might respond to the treatment are still missing. Similarly, rationales for combining immune checkpoint inhibitors with conventional therapy or targeted agents are lacking.

The goal of IMMUcan is to understand, how the immune system and tumours interact, and the impact of therapeutic interventions

Latest news

International consortium of world-class research organisations

Go to Top